Pfizer (NYSE:PFE) Trading 3.2% Higher After Analyst Upgrade

Pfizer Inc. (NYSE:PFE)’s stock price rose 3.2% during mid-day trading on Tuesday after HSBC raised their price target on the stock from $29.00 to $32.00. HSBC currently has a buy rating on the stock. Pfizer traded as high as $27.76 and last traded at $27.4720. Approximately 59,452,849 shares changed hands during trading, an increase of 27% from the average daily volume of 46,669,520 shares. The stock had previously closed at $26.61.

Other equities analysts have also recently issued research reports about the company. Bank of America lowered their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.14.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 2 data — Pfizer said its atirmociclib combination cut the risk of disease progression or death by ~40% in a randomized mid‑stage breast cancer trial, supporting the drug’s commercial and pipeline value. Read More.
• Positive Sentiment: Analyst upgrade and target lift — HSBC raised its price target from $29 to $32 and put a “buy” rating on PFE, signaling more upside in sell‑side expectations and likely supporting near‑term buying interest. Read More.
• Positive Sentiment: Deal spillover lifts peers/investors — IP Group said NAV rose after Pfizer’s acquisition of Metsera, underscoring Pfizer’s active M&A in obesity and reinforcing investor confidence in dealmaking that can add late‑stage assets. Read More.
• Neutral Sentiment: Ongoing pipeline progress — Pfizer continues to advance multiple trials (new tafamidis formulation, pediatric etrasimod, multivalent pneumococcal vaccine PG4 analysis), which supports longer‑term revenue diversification but is not an immediate revenue driver. Read More.
• Neutral Sentiment: Analyst and retail attention — Zacks and other outlets are highlighting PFE and investors are comparing Pfizer vs. peers like BMY as they weigh oncology pipeline strength; this attention can amplify moves but is not a direct fundamental change. Read More.
• Negative Sentiment: Ongoing revenue risk and loss of exclusivity — analysts and retail commentary warn that Pfizer’s COVID‑era revenue normalisation and looming patent expiries on legacy drugs remain a key risk to sustaining past revenue levels. Investors should weigh clinical wins against these structural revenue headwinds. Read More.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the company. Fiduciary Alliance LLC lifted its holdings in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after acquiring an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer in the 3rd quarter worth about $3,019,000. Vista Investment Partners LLC grew its position in Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares during the period. Money Concepts Capital Corp raised its position in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the period. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $16,613,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company’s 50 day moving average price is $26.53 and its 200-day moving average price is $25.54. The company has a market cap of $156.21 billion, a PE ratio of 20.20 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the business posted $0.63 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.